Bruker Corporation
BRKR
Peringkat dalam Saham
#2332
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Harga Saham
$55.23
Kapitalisasi Pasar
$8.42B
Perubahan (1 hari)
-0.25%
Perubahan (1 tahun)
44.93%
Negara
US
Perdagangan Bruker Corporation (BRKR)
Kategori
Healthcare
Rasio P/E untuk Bruker Corporation (BRKR)
Rasio P/E per October 2026 TTM: -79.54
Menurut laporan keuangan dan harga saham terbaru dari Bruker Corporation, rasio P/E saat ini (TTM) adalah -79.54. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar 25.18.
Riwayat rasio P/E untuk Bruker Corporation dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -79.54 | -202.99% |
| 2024 | 77.23 | 206.68% |
| 2023 | 25.18 | -26.47% |
| 2022 | 34.24 | -25.31% |
| 2021 | 45.85 | -12.87% |
| 2020 | 52.62 | 31.18% |
| 2019 | 40.11 | 55.02% |
| 2018 | 25.88 | -62.52% |
| 2017 | 69.03 | 210.18% |
| 2016 | 22.26 | -44.61% |
| 2015 | 40.18 | -30.80% |
| 2014 | 58.06 | 41.29% |
| 2013 | 41.09 | 25.89% |
| 2012 | 32.64 | 46.67% |
| 2011 | 22.26 | -22.20% |
| 2010 | 28.61 | 17.80% |
| 2009 | 24.28 | 139.77% |
| 2008 | 10.13 | -85.11% |
| 2007 | 68.00 | 64.84% |
| 2006 | 41.25 | -69.31% |
| 2005 | 134.39 | -370.97% |
| 2004 | -49.60 | 85.31% |
| 2003 | -26.76 | -35.09% |
| 2002 | -41.23 | -116.97% |
| 2001 | 243.02 | -58.74% |
| 2000 | 589.00 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 33.11 | -141.62% |
US
|
|
| 21.39 | -126.89% |
IE
|
|
| 28.94 | -136.39% |
US
|
|
| 17.34 | -121.80% |
US
|
|
| - | - |
DE
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.